Académique Documents
Professionnel Documents
Culture Documents
13711380
1371
1372 Bhatti et al: a-Lipoic acid in diabetic nephropathy
treatments for reducing the incidence and attenuating the thetized with sodium pentobarbital (40 mg/kg intraperi-
progression of diabetic complications. toneally) and their femoral vessels catheterized. Sys-
a-Lipoic acid is a sulfur-containing coenzyme involved temic blood pressure was monitored electronically using
in mitochondrial dehydrogenase reactions leading to Cardiomax-II (Columbus Instruments, Columbus, OH,
adenosine triphosphate (ATP) formation [18, 19]. a- USA) blood pressure analyzer. Following blood pres-
Lipoic acid, along with its major metabolite dihydrolipoic sure measurements, blood samples were collected by
acid (DHLA), is a potent antioxidant via scavenging of cardiac puncture for measurement of plasma creatinine.
oxygen free radicals, redox interaction with other antiox- An abdominal incision was made, the right kidney was
idants [20, 21], and inhibition of lipid peroxidation [6]. removed, dissected into cortex and medulla, and snap-
The beneficial effects of a-lipoic acid in diabetes have frozen in liquid nitrogen for O 2 measurement and
long been recognized, however, these beneficial effects Western blot analysis. The left kidney was perfused
have mainly been attributed to its glycemic control [22]. first with ice-cold phosphate-buffered saline (PBS) un-
More recently, the effects of a-lipoic acid in the treat- til cleared of blood and then with 4% paraformaldehyde
ment of diabetic end-organ complications, including dia- for morphologic analysis and immunohistochemistry.
betic nephropathy, have been reported [6, 21, 23, 24]. In
diabetic neuropathy, a-lipoic acid improves blood flow Plasma creatinine
and reduces oxidative stress in the distal nerves [25]. In
Plasma creatinine concentrations were determined us-
early diabetes, a-lipoic acid decreases vascular endothe-
ing a Beckman Creatinine Analyzer II (Brea, CA, USA)
lial growth factor (VEGF) expression and hypoxia in the
with the modified Jaffe rate method, according to the
retina [26]. In diabetic nephropathy, a-lipoic acid has
manufacturers instructions.
been shown to prevent renal insufficiency, glomerular
mesangial matrix expansion, and glomerulosclerosis by
restoring glutathione and reducing malondialdehyde lev- Urine albumin excretion (UAE)
els [22]. The aim of our study was to further elucidate the Urine albumin concentration was determined using a
mechanisms by which a-lipoic acid exerts its antioxidant Nephrat II Albumin Kit (Exocell, Inc., Philadelphia, PA,
effects and provides renoprotection in diabetic nephropa- USA) according to the manufacturers protocol.
thy.
Morphology
Four percent paraformaldehyde-fixed tissue was em-
METHODS bedded in paraffin and sectioned at 4 lm for morpho-
Animal model logic analysis. The sections were stained with periodic
acid-Schiff (PAS) (for demonstration of glycogen con-
Male Sprague-Dawley rats (Harlan, 200 g) were ran-
tent) and Massons trichrome (for demonstration of col-
domly divided into four treatment groups: nondiabetic on
lagen deposition).
control (normal rat chow) diet, nondiabetic on a-lipoic
acid (normal rat chow containing a-lipoic acid) diet, di-
abetic on control diet, and diabetic on a-lipoic acid diet, Glomerulosclerotic index
with N = 4 to 6 animals per group. a-Lipoic acid diet PAS-stained sections were examined using a Nikon
was custom prepared by Harlan Teklad and contained Eclipse E600 light microscope. Ten sections and 80
400 mg/kg of a-lipoic acid. The rats were supplemented glomeruli per section were randomly selected and the
with a-lipoic acid at a dose of 30 mg a-lipoic acid/kg body degree of glomerulosclerosis determined using a semi-
weight per day. The diabetic rats were given additional quantitative scoring method as previously described [27].
chow without a-lipoic acid to make up the difference in
the food intake. Following an overnight fast, the animals Index of tubulointerstitial fibrosis
were either given a single intraperitoneal injection of 0.1
Massons trichome-stained sections were examined us-
mol/L citrate buffer, pH 4.5 (nondiabetic) or 55 mg/kg
ing a Nikon Eclipse E600 light microscope. Forty sections
streptozotocin in 0.1 mol/L citrate buffer (diabetic). The
were randomly selected, and the degree of tubulointersti-
diabetic animals were given daily injections of insulin
tial fibrosis determined using a semiquantitative scoring
(4 to 6 U) (Lantus) (Aventis Pharmaceuticals Inc., Kansas
method as previously described [28].
City, MO, USA) to maintain blood glucose levels be-
tween 250 and 400 mg/dL. During the treatment period
(12 weeks), the animals were placed in metabolic cages NADPH-stimulate O
2 generation
every 4 weeks and urine samples collected for the mea- O
2 generation in response to stimulation with
surement of albumin excretion and creatinine clearance. NADPH was assessed by lucigenin-enhanced chemilu-
After 12 weeks of treatment, the animals were anes- minescence as previously described [29]. Briefly, cortical
Bhatti et al: a-Lipoic acid in diabetic nephropathy 1373
and medullary tissues were homogenized in PBS Table 1. Effects of a-lipoic acid on body and kidney weight and
blood glucose
then incubated with 5 lmol/L lucigenin and the ox-
idase reaction stimulated by addition of 1 mmol/L Control a-Lipoic acid
NADPH. The background-adjusted chemiluminescence Nondiabetic Diabetic Nondiabetic Diabetic
signal was sampled every second for 10 minutes and
Body weight g 440 12 347 23b 472 13a 386 26b
recorded using a tube luminometer with automated in- Kidney weight g 1.2 0.1 1.7 0.1b 1.3 0.1 1.4 0.1a
jector (AutoLumatPlus LB 953) (EG&G Berthhold, Kidney/body 2.8 0.1 4.9 0.7c 2.6 0.05 3.1 0.2a
Germany). weight
Blood glucose 89 3 336 28c 92 3 352 14c
mg/dL
Mean arterial 119 9 122 14 117 13 120 11
Renal excretion of 8-iso prostaglandin F 2a (PGF 2a ) pressure mm Hg
8-iso PGF 2a was assessed as previously described [30]. Data are expressed as mean SEM.
a <
Briefly, total 8-iso PGF 2a was purified from urine sam- P 0.05; b P < 0.05 vs. nondiabetic in same treatment group; c P < 0.01 vs.
control in same metabolic state.
ples using a phenylboronic acid column (Varian Inc., Palo
Alto, CA, USA) and eluted with ethyl acetate containing
1% methanol and assayed with an enzyme immunoassay
procedure (Cayman Chemical, Ann Arbor, MI, USA). Rafael, CA, USA). Differences were considered statisti-
cally significant at P < 0.05.
Imunohistochemistry
Paraffin sections were incubated with 10% nonimmune RESULTS
goat serum, followed by incubation with monoclonal
antibodies directed against p22phox [31] and p47phox Metabolic parameters and blood pressure
[32] for 3 hours at room temperature. The positive im- Compared to nondiabetic + control animals, body
munoreaction was detected using the Envision Plus Per- weight in the diabetic + control group was decreased
oxidase Kit (Dako Corporation, Carpentaria, CA, USA) by 1.2-fold. Similarly, body weight in the diabetic + a-
and by counterstaining with Mayers hematoxylin. Sec- lipoic acid group decreased by 1.2-fold compared to non-
tions incubated with 10% nonimmune goat serum in- diabetic + a-lipoic acid (Table 1). Kidney weight was
stead of the primary antiserum were used as negative increased by 1.4-fold in the diabetic + control group com-
controls. pared to nondiabetic + control but was not significantly
changed in the diabetic + a-lipoic acid group, as com-
pared to nondiabetic + a-lipoic acid (Table 1). Kidney to
Western blotting body weight ratio was also increased in the diabetic + con-
Homogenized samples from the renal cortex and trol group compared to nondiabetic + control (1.8-fold),
medulla were separated on 18% sodium dodecyl sul- whereas kidney/body weight remained similar in nondi-
fate (SDS-PAGE) gels and the proteins were trans- abetic + a-lipoic acid and diabetic + a-lipoic acid ani-
ferred to nitrocellulose membranes. The membranes mals (Table 1). Overall, a-lipoic acid treatment resulted
were blocked with 5% nonfat milk, followed by primary in significant reductions in kidney weight (1.2-fold) and
antibodies as described for immunohistochemistry at 4 C kidney/body weight ratio (1.6-fold) in diabetic animals
overnight. The membranes were washed and incubated (Table 1).
with horseradish peroxidase-conjugated goat antimouse Blood glucose was threefold higher in diabetic com-
IgG, and the proteins were visualized by chemilumines- pared to the nondiabetic group (Table 1). In the diabetic
cence (KPL, Gaithersburg, MD, USA). The densities of group, no differences in blood glucose levels were ob-
specific bands were quantitated by densitometry using served between the control and a-lipoic acidtreated rats.
Scion Image beta (version 4.02) software. Band densities No differences in mean arterial pressure (MAP) were ob-
were normalized to the total amount of protein loaded served between any of the treatment groups (Table 1).
in each well, as determined by densitometric analysis of
gels stained with Coomassie blue.
UAE and plasma creatinine
UAE increased by threefold with no change in plasma
Statistical analysis creatinine in the diabetic + control group compared to
Data are expressed as mean SEM, except for albu- nondiabetic + control (Table 2). Consistent with its pro-
minuria, which is expressed as geometric mean x/ toler- tective properties, a-lipoic acid treatment reduced albu-
ance factor, and were analyzed with a two-way analysis min excretion by 1.6-fold in diabetic animals. In con-
of variance (ANOVA) followed by a Bonferroni post hoc trast, a-lipoic acid actually increased albumin excretion
test, using the SigmaStat software (Jandel Scientific, San (1.6-fold) and increased plasma creatinine (1.2-fold) in
1374 Bhatti et al: a-Lipoic acid in diabetic nephropathy
Urine albumin excrection mg/24 hours 8.8 x/1.3 28.1 x/4.6d 14.2x/1.2a 17.8 x/1.2b
Plasma creatinine lmol/L 59 6 68 6 86 9.0a 69 7c
Glomerulosclerotic index 0.22 0.01 0.55 0.04d 0.61 0.04b 0.36 0.03b,d
Cortical tubulointerstial fibrosis index 0.42 0.2 1.52 0.05d 1.29 0.2b 1.10 0.05a
Medullary tubulointerstitial fibrosis index 0.56 0.2 2.0 0.1d 0.72 0.2 0.49 0.07a
Data are expressed as mean SEM except for urine albumin excretion, which is expressed as geometric mean x/ tolerance factor.
a <
P 0.05; b P < 0.01 vs. control in same metabolic state; c P < 0.05; d P < 0.05 vs. nondiabetic in same treatment group.
A ND D
cd
C G
pt
G pt
cd
cd
pt
cd
LA G
G
pt
Fig. 1. Periodic acid-Schiff (PAS) and Massons trichrome stains. (A) PAS-stained sections of the renal cortex of the nondiabetic (ND) and
diabetic (D) kidneys treated with a-lipoic acid (LA). Glomerulosclerosis (G) with thickening of basement membranes of the proximal tubules (pt),
mesangial expansion (arrow heads), and inflammatory infiltrates (arrows). Massons trichrome-stained sections of the renal cortex (B) and medulla
(C) of nondiabetic (ND) and diabetic (D) kidneys treated with a-lipoic acid (LA). Outlined are areas of tubulointerstitial fibrosis, accumulation of
extracellular matrix (ECM) proteins, capillary occlusion, and increased proliferation of interstitial fibroblasts (original magnification 400).
nondiabetic animals compared to nondiabetic + controls the diabetic group by 1.5-fold compared to diabetic +
(Table 2). control; however, treatment of nondiabetic animals with
a-lipoic acid was associated with moderate glomeru-
losclerosis, similar to that observed in the diabetic + con-
Glomerulosclerosis and tubulointerstitial fibrosis trol group (Fig. 1A). Mild tubulointerstitial fibrosis, char-
The kidneys of nondiabetic + control rats exhibited acterized by accumulation of extracellular matrix (ECM),
normal cortical (Fig. 1) and medullary (Fig. 1B) morphol- tubular dilatation, and atrophy was observed in the dia-
ogy. Mild glomerulosclerosis, characterized by glomeru- betic + control animals (Fig. 1B). The tubulointerstitial
lar basement membrane thickening and mesangial fibrosis index was 3.6-fold greater in both the renal cor-
expansion was observed in diabetic + control animals, tex and medulla compared to that of nondiabetic + con-
with a 2.6-fold greater glomerulosclerotic index com- trol (Table 2). Treatment with a-lipoic acid reduced tubu-
pared to that of nondiabetic + control (Table 2). Treat- lointerstitial fibrosis index in the renal cortex (1.3-fold)
ment with a-lipoic acid reduced glomerulosclerosis in and medulla (1.4-fold) in the diabetic group compared to
Bhatti et al: a-Lipoic acid in diabetic nephropathy 1375
B ND D A
125
C
LA
O2 generation, RLU/mg
100 bb
C
75
50
a aa
25
.
LA
0
ND D
B
100
ND D C
LA
C
50 aa b
a
25 b
0
LA ND D
p22phox p47phox
ND
ND+LA
diabetic nephropathy, are detrimental to the healthy kid- diabetic kidney, and, according to our findings, in con-
ney. In nondiabetic rats, treatment with a-lipoic acid is as- trast to the diabetic animals where a-lipoic acid exerts
sociated with a decline in creatinine clearance, increases a protective effect, a-lipoic acid appears to have a dele-
in albuminuria, glomerulosclerosis, tubulointerstitial fi- terious effect in nondiabetic animals. Scott et al [45] re-
brosis, and increases in NADPH-induced O 2 generation ported that DHLA, the reduced metabolite of a-lipoic
and 8-iso excretion. These changes are similar to those acid, may have pro-oxidant effects, via its ability to re-
observed in the kidneys of untreated diabetic rats. It is duce iron and generate reactive sulfur-containing radicals
quite surprising that none of the previous studies exam- that can damage proteins such as alpha 1-antiproteinase
ining the effects of a-lipoic acid in diabetic nephropathy and creatine kinase [45]. a-lipoic acid and DHLA have
have ever reported the effects of a-lipoic acid in the non- also been shown to stimulate O 2 production in rat liver
1378 Bhatti et al: a-Lipoic acid in diabetic nephropathy
p22phox p47phox
22 kD 47 kD
1.0 1.0 C
Arbitrary densitometry
Arbitrary densitometry
C LA
LA bb
bb a
units
units
Cortex a
0.5 0.5
aa
0.0 0.0
ND D ND D
47 kD
22 kD
3
3 C
Arbitrary densitometry
Arbitrary densitometry
C
LA b LA
a a b
2 2
units
units
Medulla
aa
b 1 a
1
0 0
ND D ND D
Fig. 5. Renal expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit protein in nondiabetic (ND) and diabetic (D)
kidneys treated with a-lipoic acid (LA). Top panels in each graph are representative Western blots. Bottom panels in each graph are densitometric
analyses of the blots shown above. Data are expressed as mean SEM (N = 6 per group). a P < 0.05; aa P < 0.01 vs. control in same metabolic state;
b P < 0.05; bb P < 0.01 vs. nondiabetic in the same treatment group.
mitochondria and submitochondrial particles and in cul- in this study. Another human trial reported that a-lipoic
tured 3T3-L1 adipocytes in response to high glucose stim- acid at a dose of 600mg/day for 8 weeks in healthy volun-
uli [46]. Consistent with these findings, we observed that teers (age group 38 years of age) reduced 8-iso excre-
a-lipoic acid increases NADPH-induced O 2 and expres- tion [50]; however, no other markers of oxidative stress
sion of p47phox in the nondiabetic kidney and thus by or renal function were reported. In experimental animal
acting as a pro-oxidant, causes deleterious effects in the models, a-lipoic acid has been used in the range of 25
healthy kidney. to 100 mg/kg/day [24, 34, 35]. It is quite intriguing, how-
The detrimental effects of a-lipoic acid on renal func- ever, that none of these animal studies report the findings
tion and pathology may be dose-related. We have cho- in the control, healthy animals. Thus, our results stress
sen a dose of a-lipoic acid previously reported to have the importance of monitoring the dose of a-lipoic acid
beneficial effects in the diabetic kidney [34]. Although supplementation, duration of treatment and its potential
our studies confirm these findings, we also show that this harmful effects in the healthy kidney.
same dose of a-lipoic acid (30 mg/kg body weight) com- Based on the findings of our study, we conclude that
promises renal structure and function under nondiabetic a-lipoic acid may exert both pro- and antioxidant effects,
conditions. A wide range of daily recommended doses of depending on the underlying physiologic and metabolic
a-lipoic acid have been reported and used in human tri- state. While a-lipoic acid is renoprotective in diabetic
als, ranging from 100 to 1800 mg/day [4749]; although nephropathy, it may have potential harmful effects in an
little attention has been paid to this dose relative to body otherwise healthy kidney.
weight, duration of the trial or underlying physiologic
state, especially relating to renal function. In a trial us-
ACKNOWLEDGMENTS
ing dietary supplementation with a-lipoic acid at a dose
of 600 mg/day for 3 months, a reduction of UAE was This work was supported by the American Diabetes Association
Scientist Development Grant, the National Kidney Foundation (DC
observed in type 2 diabetic patients [48]; however, no ef- Sections) (Grant-in-aid to D.C.M.), and the National Heart, Lung,
fects of a-lipoic acid in healthy individuals were reported and Blood Institute (HL-66575 to M.T.Q.). The authors would like to
Bhatti et al: a-Lipoic acid in diabetic nephropathy 1379
acknowledge the technical assistance of Mr. Shoaib Afridi and Mr. Gar- 21. BAST A, HAENEN G: Lipoic acid: a multifunctional antioxidant. Bio-
rett Fitzgerald. factors 17:207213 2003
22. MELHEM MF, CRAVEN PA, LIACHENKO J, DE RUBERTIS FR: Alpha-
Reprint requests to Christine Maric, Ph.D., Department of Medicine, lipoic acid attenuates hyperglycemia and prevents glomerular
Division of Nephrology and Hypertension, Georgetown University Med- mesangial matrix expansion in diabetes. J Am Soc Nephrol 13:108
ical Center, 394 Bldg. D, 4000 Reservoir Rd. NW, Washington, DC 20057. 116, 2002
E-mail: cm255@georgetown.edu 23. MARITIM AC, SANDERS RA, WATKINS JB: Effects of alpha-lipoic acid
on biomarkers of oxidative stress in streptozotocin-induced diabetic
REFERENCES rats. J Nutr Biochem 14:288294, 2003
24. OBROSOVA IG, FATHALLAH L, LIU E, NOUROOZ-ZADEH J: Early ox-
1. KOO JR, NI Z, OVIESI F, VAZIRI ND: Antioxidant therapy poten- idative stress in the diabetic kidney: Effect of DL-alpha-lipoic acid.
tiates antihypertensive action of insulin in diabetic rats. Clin Exp Free Radic Biol Med 34:186195, 2003
Hypertens 24:333344, 2002 25. NAGAMATSU M, NICKANDER K, SCHMELZER J, et al: Lipoic acid im-
2. KITADA M, KOYA D, SUGIMOTO T, et al: Translocation of glomeru- proves nerve blood flow, reduces oxidative stress, and improves dis-
lar p47phox and p67phox by protein kinase C-beta activation is tal nerve conduction in experimental diabetic neuropathy. Diabetes
required for oxidative stress in diabetic nephropathy. Diabetes Care 18:11601167, 1995
52:26032614, 2003 26. OBROSOVA IG, FATHALLAH L, GREENE DA: Early changes in lipid
3. LI JM, SHAH AM: ROS generation by nonphagocytic NADPH oxi- peroxidation and antioxidative defense in diabetic rat retina: Effect
dase: Potential relevance in diabetic nephropathy. J Am Soc Nephrol of DL-alpha-lipoic acid. Eur J Pharmacol 398:139146, 2000
14:S221S226, 2003 27. SAITO T, SUMITHRAN E, GLASGOW EF, ATKINS RC: The enhance-
4. FORBES JM, THALLAS V, THOMAS MC, et al: The breakdown of pre- ment of aminonucleoside nephrosis by the co-administration of pro-
existing advanced glycation end products is associated with reduced tamine. Kidney Int 32:691699, 1987
renal fibrosis in experimental diabetes. FASEB J 17:17621764, 2003 28. TANEDA S, PIPPIN JW, SAGE EH, et al: Amelioration of diabetic
5. EVANS JL, GOLDFINE ID, MADDUX BA, GRODSKY GM: Oxidative nephropathy in SPARC-null mice. J Am Soc Nephrol 14:968980,
stress and stress-activated signaling pathways: A unifying hypothe- 2003
sis of type 2 diabetes. Endocr Rev 23:599622, 2002 29. KITIYAKARA C, CHABRASHVILI T, CHEN Y, et al: Salt intake, oxidative
6. DINCER Y, TELCI A, KAYALI R, et al: Effect of alpha-lipoic acid on stress, and renal expression of NADPH oxidase and superoxide
lipid peroxidation and anti-oxidant enzyme activities in diabetic dismutase. J Am Soc Nephrol 14:27752782, 2003
rats. Clin Exp Pharmacol Physiol 29:281284, 2002 30. SCHNACKENBERG CG, WILCOX CS: Two-week administration of tem-
7. ISHII N, PATEL KP, LANE PH, et al: Nitric oxide synthesis and oxida- pol attenuates both hypertension and renal excretion of 8-iso
tive stress in the renal cortex of rats with diabetes mellitus. J Am prostaglandin f2alpha. Hypertension 33:424428, 1999
Soc Nephrol 12:16301639, 2001 31. BURRITT JB, QUINN MT, JUTILA MA, et al: Topological mapping of
8. PRIVRATSKY JR, WOLD LE, SOWERS JR, et al: AT 1 blockade prevents neutrophil cytochrome b epitopes with phage-display libraries. J
glucose-induced cardiac dysfunction in ventricular myocytes: role of Biol Chem 270:1697416980, 1995
the AT 1 receptor and NADPH oxidase. Hypertension 42:206212, 32. DE LEO FR, ULMAN KV, DAVIS AR, et al: Assembly of the human
2003 neutrophil NADPH oxidase involves binding of p67phox and flav-
9. KASHIWAGI M, SHINOZAKI M, HIRAKATA H, et al: Locally activated ocytochrome b to a common functional domain in p47phox. J Biol
renin-angiotensin system associated with TGF-beta1 as a major fac- Chem 271:1701317020, 1996
tor for renal injury induced by chronic inhibition of nitric oxide 33. CHABRASHVILI T, TOJO A, ONOZATO ML, et al: Expression and
synthase in rats. J Am Soc Nephrol 11:616624, 2000 cellular localization of classic NADPH oxidase subunits in the
10. ONOZATO ML, TOJO A, GOTO A, et al: Oxidative stress and nitric spontaneously hypertensive rat kidney. Hypertension 39:269274,
oxide synthase in rat diabetic nephropathy: effects of ACEI and 2002
ARB. Kidney Int 61:186194, 2002 34. MELHEM MF, CRAVEN PA, DERUBERTIS FR: Effects of dietary supple-
11. VEELKEN R, HILGERS KF, HARTNER A, et al: Nitric oxide synthase mentation of alpha-lipoic acid on early glomerular injury in diabetes
isoforms and glomerular hyperfiltration in early diabetic nephropa- mellitus. J Am Soc Nephrol 12:124133, 2001
thy. J Am Soc Nephrol 11:7179, 2000 35. MELHEM MF, CRAVEN PA, LIACHENKO J, DERUBERTIS FR: Alpha-
12. KOMERS R, LINDSLEY JN, OYAMA TT, et al: Role of neuronal nitric lipoic acid attenuates hyperglycemia and prevents glomerular
oxide synthase (NOS1) in the pathogenesis of renal hemodynamic mesangial matrix expansion in diabetes. J Am Soc Nephrol 13:108
changes in diabetes. Am J Physiol Renal Physiol 279:F573F583, 116, 2002
2000 36. CATHERWOOD MA, POWELL LA, ANDERSON P, et al: Glucose-induced
13. JE HD, SHIN CY, PARK HS, et al: The comparison of vitamin C oxidative stress in mesangial cells. Kidney Int 61:599608, 2002
and vitamin E on the protein oxidation of diabetic rats. J Auton 37. MERVAALA E, FINCKENBERG P, LAPATTO R, et al: Lipoic acid supple-
Pharmacol 21:231236, 2001 mentation prevents angiotensin II-induced renal injury. Kidney Int
14. OBROSOVA IG, FATHALLAH L, STEVENS MJ: Taurine counteracts ox- 64:501508, 2003
idative stress and nerve growth factor deficit in early experimental 38. HAMADA Y, ARAKI N, KOH N, et al: Rapid formation of advanced gly-
diabetic neuropathy. Exp Neurol 172:211219, 2001 cation end products by intermediate metabolites of glycolytic path-
15. JACHEC W, TOMASIK A, TARNAWSKI R, CHWALINSKA E: Evidence of way and polyol pathway. Biochem Biophys Res Commun 228:539
oxidative stress in the renal cortex of diabetic rats: Favourable effect 543, 1996
of vitamin E. Scand J Clin Lab Invest 62:8188, 2002 39. DERUBERTIS F, CRAVEN P: Activation of protein kinase C in glomeru-
16. KOYA D, HAYASHI K, KITADA M, et al: Effects of antioxidants in lar cells in diabetes. Mechanisms and potential links to the patho-
diabetes-induced oxidative stress in the glomeruli of diabetic rats. genesis of diabetic glomerulopathy. Diabetes 43:18, 1994
J Am Soc Nephrol 14:S250S253, 2003 40. HA H, KIM K: Pathogenesis of diabetic nephropathy: the role of ox-
17. CRAVEN PA, DERUBERTIS FR, KAGAN VE et al: Effects of supple- idative stress and protein kinase C. Diabetes Res Clin Pract 45:147
mentation with vitamin C or E on albuminuria, glomerular TGF- 151, 1999
beta, and glomerular size in diabetes. J Am Soc Nephrol 8:1405 41. FUMO P, KUNCIO G, ZIYADEH F: PKC and high glucose stimulate
1414, 1997 collagen alpha 1 (IV) transcriptional activity in a reporter mesangial
18. PACKER L, WITT EH, TRITSCHLER HJ: alpha-Lipoic acid as a biolog- cell line. Am J Physiol 267:F632F638, 1994
ical antioxidant. Free Radic Biol Med 19:227250, 1995 42. YILMAZ O, OZKAN Y, YILDIRIM M, et al: Effects of alpha lipoic acid,
19. CARREAU JP: Biosynthesis of lipoic acid via unsaturated fatty acids. ascorbic acid-6-palmitate, and fish oil on the glutathione, malon-
Methods Enzymol 62:152158, 1979 aldehyde, and fatty acids levels in erythrocytes of streptozotocin
20. MOINI H, PACKER L, SARIS N: Antioxidant and prooxidant activities induced diabetic male rats. J Cell Biochem 86:530539, 2002
of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 43. ETOH T, INOGUCHI T, KAKIMOTO M, et al: Increased expression of
182:8490, 2002 NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of
1380 Bhatti et al: a-Lipoic acid in diabetic nephropathy
streptozotocin-induced diabetic rats and its reversibity by interven- controlled trial (ALADIN II). Alpha lipoic acid in diabetic neu-
tive insulin treatment. Diabetologia 46:14281437, 2003 ropathy. Free Radic Res 31:171179, 1999
44. ZHAN CD, SINDHU RK, VAZIRI ND: Up-regulation of kidney 48. BORCEA V, NOUROOZ-ZADEH J, WOLFF S, et al: alpha-Lipoic acid de-
NAD(P)H oxidase and calcineurin in SHR: Reversal by lifelong creases oxidative stress even in diabetic patients with poor glycemic
antioxidant supplementation. Kidney Int 65:219227, 2004 control and albuminuria. Free Radic Biol Med 26:14951500,
45. SCOTT B, ARUOMA O, EVANS P, et al: Lipoic and dihydrolipoic acids 1999
as antioxidants. A critical evaluation. Free Radic Res 20:119133, 49. RUHNAU KJ, MEISSNER HP, FINN JR, et al: Effects of 3-week oral
1994 treatment with the antioxidant thioctic acid (alpha-lipoic acid) in
46. MOINI H, PACKER L, SARIS NE: Antioxidant and prooxidant activi- symptomatic diabetic polyneuropathy. Diabet Med 16:10401043,
ties of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Phar- 1999
macol 182:8490, 2002 50. MARANGON K, DEVARAJ S, TIROSH O, et al: Comparison of the ef-
47. RELJANOVIC M, REICHEL G, RETT K, et al: Treatment of diabetic fect of alpha-lipoic acid and alpha-tocopherol supplementation on
polyneuropathy with the antioxidant thioctic acid (alpha-lipoic measures of oxidative stress. Free Radic Biol Med 27:11141121,
acid): A two year multicenter randomized double-blind placebo- 1999